Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure

Over the last decade, treatment for heart failure with reduced ejection fraction (HFrEF) has advanced, with the incremental addition of novel evidence-based medical therapies. The landmark PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study showed that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan was superior to enalapril in reducing risk...